Cannabinoids in the management of spasticity associated with multiple sclerosis

Código QR

Cannabinoids in the management of spasticity associated with multiple sclerosis

Anna Maria Malfitano, Maria Chiara Proto, Maurizio BifulcoDipartimento di Scienze Farmaceutiche, Universit&agrave; degli Studi di SalernoAbstract: The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies sugge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2f1b1e7ad19f4caf867e311d798728b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu R, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij R, et al.
Publicado: (2015)

Cognitive dysfunction in pediatric multiple sclerosis
por: Suppiej A, et al.
Publicado: (2014)

The Multiple Sclerosis Treatment Optimization Program
por: Annette Langer‐Gould, et al.
Publicado: (2021)

Neurobehavioral burden of multiple sclerosis with nanotheranostics
por: Sriramoju B, et al.
Publicado: (2015)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke C, et al.
Publicado: (2011)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Clemens Warnke, et al.
Publicado: (2009)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: David W Brandes
Publicado: (2010)

Association between smoking and cognitive impairment in multiple sclerosis
por: Özcan ME, et al.
Publicado: (2014)

Gut microbiome is associated with multiple sclerosis activity in children
por: Mary K. Horton, et al.
Publicado: (2021)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013)

Measuring treatment response to advance precision medicine for multiple sclerosis
por: Peter A. Calabresi, et al.
Publicado: (2021)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey D, et al.
Publicado: (2015)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop F, et al.
Publicado: (2013)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
por: Fabricio Gonz&aacute;lez-Andrade, et al.
Publicado: (2010)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes KC
Publicado: (2011)

Attention deficits in Japanese multiple sclerosis patients with minor brain lesion loads
por: Takeda A, et al.
Publicado: (2011)

Walking impairment in patients with multiple sclerosis: exercise training as a treatment option
por: Robert W Motl, et al.
Publicado: (2010)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Julie A Murphy, et al.
Publicado: (2010)

Cluster headache as a first manifestation of multiple sclerosis: case report and literature review
por: Mijajlović MD, et al.
Publicado: (2014)

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
por: Kachuck NJ
Publicado: (2011)

Periodic limb movements during REM sleep in multiple sclerosis: a previously undescribed entity
por: Veauthier C, et al.
Publicado: (2015)

Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options
por: Wang S, et al.
Publicado: (2014)

Review of the clinical evidence for interferon &beta; 1a (Rebif&reg;) in the treatment of multiple sclerosis
por: Francesco Manfredonia, et al.
Publicado: (2008)

Effect of acetazolamide for long-lasting paroxysmal dystonia in a patient with multiple sclerosis: a case report and review of literature
por: Hsieh PC, et al.
Publicado: (2013)

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing&ndash;remitting multiple sclerosis?
por: Mezei Z, et al.
Publicado: (2012)

Disconnection of the hippocampus and amygdala associated with lesion load in relapsing–remitting multiple sclerosis: a structural and functional connectivity study
por: Zhou F, et al.
Publicado: (2015)

Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report
por: De Pasquale C, et al.
Publicado: (2014)

Current and emerging treatments for amyotrophic lateral sclerosis
por: Stefano Zoccolella, et al.
Publicado: (2009)

The role of microglia in multiple sclerosis
por: Luo C, et al.
Publicado: (2017)

Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
por: Introna A, et al.
Publicado: (2018)

The hospital anxiety and depression scale, in patients with multiple sclerosis
por: Pais-Ribeiro JL, et al.
Publicado: (2018)

Neuropsychiatric assessments in patients with multiple sclerosis in early phases and with low disability
por: Schmidt SL, et al.
Publicado: (2018)

Cognitive status in patients with multiple sclerosis in Lanzarote
por: Pérez-Martín MY, et al.
Publicado: (2016)

Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease
por: Cui F, et al.
Publicado: (2015)

The use of natalizumab for multiple sclerosis
por: Brandstadter R, et al.
Publicado: (2017)

Current and emerging treatment options in the management of Friedreich ataxia
por: Michelangelo Mancuso, et al.
Publicado: (2010)

Restless legs syndrome: differential diagnosis and management with rotigotine
por: Giovanni Merlino, et al.
Publicado: (2009)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau J, et al.
Publicado: (2018)

Prevalence of Pediatric Onset Multiple Sclerosis in Saudi Arabia
por: Reem Bunyan, et al.
Publicado: (2021)